Leukemia patients who switched kinase inhibitors had favorable outcomes
Tuesday, December 8, 2015 - 06:21
in Health & Medicine
Chronic lymphocytic leukemia patients who stopped taking the kinase inhibitors, ibrutinib or idelalisib, had mostly favorable outcomes when they switched to the alternate therapy, report investigators.